Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Stock Information for Portage Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Portage Biotech Inc.

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
Portage Biotech Announces Completion of $2.15 Million Private Financing
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.